NASH News – Tackling Fatty Liver Disease
As the field of NASH is on the verge of clinical and diagnostic breakthroughs, discover how Global Liver Institute (GLI) is promoting healthier living through our personalized nutrition solution, as well as how we are advocating for greater inclusion in clinical trials, particularly for individuals with obesity, recognizing the role of drug safety and efficacy.
GLI APPetite™ – Empowering Healthier Lives Through Personalized Nutrition
We believe in the power of food as medicine and know that choosing the right foods can be difficult. That’s why we’ve teamed up with NutriStyle to simplify healthier eating for you. By blending the latest nutritional insights with your food preferences and lifestyle, GLI APPetite™ creates custom meal plans to support your journey toward a healthier life.
FDA Workshop: Use of Biomarkers for Diagnosing and Assessing Treatment Response in Noncirrhotic NASH Trials
FDA is hosting this workshop to update key stakeholders on the state-of-the-art use of biomarkersand noninvasive tests (NITs) based on recent advances in nonalcoholic steatohepatitis (NASH)/metabolic dysfunction associated steatohepatitis (MASH) clinical trials. With a growing focus on developing NITs for detecting fibrosis stages and cirrhosis, this workshop will address knowledge gaps, discuss available evidence, and explore the potential of these tests for assessing clinical efficacy in advanced liver fibrosis cases.
Register for Day 1: Mon, Sep 18 9:00 AM – 4:45 PM ET
Register for Day 2: Tue, Sep 19 9:00 AM – 5:15 PM ET
Assessments Of Drug Safety And Effectiveness Continue To Fail People With Obesity
As a dedicated member of the Stop Obesity Alliance, GLI is actively collaborating with partners to promote greater inclusion of individuals with obesity in clinical trials. This Health Affairs article highlights the connection between obesity and liver diseases such as NAFLD and NASH, stressing the importance of mandatory consideration for their impact on the safety and efficacy of lipophilic drugs in clinical trials.
The FNIH Announces Study Results Showing That Liver Disease Can Be Diagnosed Using Noninvasive Blood Tests
FNIH’s recent study, featured in Nature Medicine, highlights the potential of noninvasive blood tests for diagnosing NASH, moving closer to FDA approval. This promising development could reduce the need for painful liver biopsies, lower clinical trial costs, and improve access to care. The study measured five biomarkers’ performance, with four outperforming current lab tests, offering hope for a new diagnostic standard and increased interest in NASH drug development.
Join us at our upcoming NASH Council Special Meeting on October 5th! We’re thrilled to host a special guest, Dr. Frank Anania, Acting Director of the Division of Hepatology and Nutrition at the U.S. Food and Drug Administration. For meeting details, reach out to firstname.lastname@example.org.
A3: The Learning Experience
Washington DC, September 30 – October 2, 2023
Liver patients, their loved ones, and clinician advocates will be gathering in Washington, DC, at the end of the month to gain critical knowledge and skills for effective liver patient advocacy! Experts in the following topics will equip advocates to effect change in their communities: liver health basics, techniques in media and storytelling, the research and development process, health insurance and coverage, collaboration with policymakers, and more!